Average Co-Inventor Count = 8.47
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Novartis Ag (12 from 3,923 patents)
2. Astrazeneca Ab (10 from 1,500 patents)
3. Paloma Pharmaceuticals, Inc. (1 from 3 patents)
23 patents:
1. 11833142 - 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
2. 11530213 - Naphthyridinone derivatives and their use in the treatment of arrhythmia
3. 11427586 - 1,2,4-oxadiazole derivatives as liver X receptor agonists
4. 11185537 - 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
5. 10844055 - Naphthyridinone derivatives and their use in the treatment of arrhythmia
6. 10266531 - Naphthyridinone derivatives and their use in the treatment of arrhythmia
7. RE46558 - Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
8. 8541432 - Heterobicyclic carboxamides as inhibitors for kinases
9. 8501756 - Heterobicyclic carboxamides as inhibitors for kinases
10. 8492393 - Heterobicyclic carboxamides as inhibitors for kinases
11. 8486954 - Heterobicyclic carboxamides as inhibitors for kinases
12. 8431584 - Heterobicyclic carboxamides as inhibitors for kinases
13. 8377939 - Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842
14. 8377940 - Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842
15. 8242125 - Heterobicyclic carboxamides as inhibitors for kinases